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Abstract
Introduction. Lung cancer is the leading cause of death from cancer in developed countries. Radiological imaging methods
are the basic methods in early diagnosis of this disease. TNM classification is a very important tool for optimal treatment in
non-small lung cancer (NSCLC). Conventional radiological techniques allow the evaluation of the stage on the basis of
anatomical changes only, while PET-CT provides information about the biochemical processes that may precede anatomical
changes. The aim of this study was to compare the accuracy and sensitivity of CT and PET-CT in the staging of NSCLC.
Material and methods. The study was conducted on a group of 99 patients with NSCLC diagnosed at the National
Tuberculosis and Lung Diseases Research Institute in the period from January 2008 to May 2010. CT and PET-CT were
performed in all patients. Histological or cytological examination of the material obtained from biopsy, bronchoscopy,
mediastinoscopy, and intraoperatively was the reference test. TNM classification was performed independently after CT
and PET-CT.
Results and conclusions. It has been shown that PET-CT is a more accurate and sensitive method than CT in the staging
process in NSCLC. PET-CT allowed the correct classification of the T, N, M, and total  TNM  in, respectively, 97%,  95%, 99%,
and 89% of cases, while for CT it was, respectively,  95%, 84%, 84%, and 68% (p = 0.0002).
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Introduction
High mortality in lung cancer patients makes
it one of the most significant healthcare issues in
most countries. Lung cancer is the most common
malignancy and causes most malignancy-related
deaths worldwide [1–4]. No significant improve-
ment in therapy outcome has been obtained as yet,
despite constant progress in diagnostics and treat-
ment [5–9]. Five-year overall survival rate for lung
cancer patients in the USA is currently 16%, whe-
reas in Europe the respective index is 10%. Poland
is one of the countries with highest incidence and
mortality rates due to this disease.
The rate of increase in both morbidity and
mortality due to lung cancer has been slowing
down in the last decade as compared to previous
ones. There are many factors implicated in incre-
asing incidence of the disease, including, in first
place, widespread tobacco smoking. Increasing life
expectancy, industry-related environmental pollu-
tion, genetic factors, and dietary habits also play
important roles in the etiology of lung cancer.
Differences in incidence of lung cancer de-
pend on age, sex, ethnic background, and geogra-
phical location. The choice of therapeutic strategy
and prognosis in non-small lung cancer (NSCLC)
depend on disease stage.
In the 1990s, studies on low-dose computed
tomography (CT) in early detection of lung cancer
in high-risk patients were initiated. Similary to
classical radiological modalities, low emission dose
CT permits detection of smaller and less advanced
lesions. Preliminary data from studies on low-dose
CT screening for lung cancer showed similar mor-
tality rates to non-screened patients, with 4.4 de-
aths per 1,000 persons per year [10, 11].
Screening yields a high percentage of false
positive results, which in turn lead to many unne-
cessary invasive procedures [12].
However, one of the most recent publications
showed a decrease in mortality in patients screened
by low dose CT, which may change earlier views
on the issue [13].
The TNM classification (tumour, node, meta-
stasis), defined by the American Joint Committee
on Cancer (AJCC), is a tool of utmost importance
in prognostic assessment and choice of optimal the-
rapeutic strategy. Adequate diagnostic procedures
performed according to the TNM principles for
NSCLC are crucial for best treatment outcomes.
The TNM classification is based on assessment
of tumour size, involvement of regional lymph
nodes, and presence of distant metastases. In
NSCLC, surgery is performed in stages IA, IB, IIA,
and IIB disease as well as in selected patients with
stage IIIA disease.
Computed tomography (CT) is a technique
applied for NSCLC staging on a routine basis, ena-
bling accurate assessment of tumour size, status of
regional lymph nodes, and potential distant meta-
stases within the investigated anatomical areas.
The role of CT is, however, limited in the assess-
ment of mediastinal lymph nodes since morpho-
logical staging criteria, based on measurement of
lymph node dimensions, include no information
on the potential presence of so-called micrometa-
stases. Evaluation of lymph node groups is curren-
tly performed using positron emission tomography
(PET) in lung cancer patients with CT-negative
mediastinal lymph nodes under qualification for
surgery. This modality enables detection of meta-
stases in normally-sized mediastinal lymph nodes.
The PET-CT scanning combines the advantages of
modalities, permitting accurate anatomical asses-
sment and a more sensitive evaluation of metabo-
lic tissue activity. This method provides informa-
tion on biochemical phenomena that may precede
the appearance of identifiable anatomical lesions.
Combined PET-CT scanning began to replace in-
dependent CT and PET assessments from 2001.
The aim of the study was to compare the dia-
gnostic accuracy of multidetector-row computed
tomography and PET-CT in staging of lung cancer.
Material and methods
The study population included 99 patients
with NSCLC (tumour size of more than10 mm),
diagnosed in the National Tuberculosis and Lung
Diseases Research Institute in Warsaw between
January 2008 and May 2010. Staging was perfor-
med according to the principles of the 6th edition
of the TNM classification, which was edited in
2007. The PET-CT investigations were performed
in two institutions: Euromedic, Warsaw (centre A;
GE Discovery STE device) and the Department of
Nuclear Medicine of the Medical University of
Warsaw (centre B; Siemens Biograph Truepoint64
device). Radiopharmaceutical fluoro- 2deoxy-D-
glucose (FDG) was administered intravenously in
each patient prior to PET-CT scanning. The measu-
red activity of FDG was 320–400 MBq in centre A
and 250–450 MBq in centre B.
Radiopharmaceuticals were administered 45
minutes prior to PET-CT scanning in centre A and
60 minutes before onset of the procedure in centre
B. An additional scanning session (so-called delay-
ed scan) was performed in selected patients dia-
gnosed in centre B; this scanning covered thoracic
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field only and was performed after 120 minutes.
Standardized uptake value (SUVmax) in the tumo-
ur was assessed during the PET-CT scan. Additio-
nal measurements of SUVmax 120 minutes after
administration of radiopharmaceutical were per-
formed in 25/27 patients (92.6%) at centre B. Thre-
shold value for benign lesions was set at or below
2.5, as described in the literature. The results of
the PET-CT scanning were evaluated by speciali-
sts in nuclear medicine.
Single phase CT scanning after contrast me-
dium administration, using spiral scanning tech-
nique, was performed in all the studied patients.
All thoracic CT scans were taken at the National
Tuberculosis and Lung Diseases Research Institu-
te in Warsaw using the Siemens Somatom Sensa-
tion 16-detector-row device, and evaluated by spe-
cialists in radiology.
The TNM classification was assigned inde-
pendently after PET-CT and CT. The result of
the histopathological tissue examination was
used for reference in each patient. Tissue and
cell samples for morphological evaluation were
obtained through mediastinoscopy and endo-
bronchial ultrasound-guided transbronchial
needle aspiration (EBUS-TBNA) and/or from
intraoperative sampling (so-called frozen sec-
tion). All samples were evaluated by speciali-
sts in pathomorphology.
The combined radiological staging data were
then compared with histopathological findings,
and basic diagnostic accuracy parameters were
calculated for PET-CT and CT.
Calculations were based on data charts accor-
ding to the statistical test theory. These included
patients with positive (T+) and negative (T–) re-
sults of the given test in subjects with or without
the disease:
— TP (true positives): number of patients having
the disease, in whom the result of the test was
positive, i.e. representing true positive results;
— FP (false positives): number of patients not ha-
ving the disease, in whom the result of the test
was positive, i.e. representing false positive re-
sults;
— FN (false negatives): number of patients ha-
ving the disease, in whom the result of the test
was negative, i.e. representing false negative
results;
— TN (true negatives): number of patients not ha-
ving the disease, in whom the result of the test
was negative, i.e. representing true negative re-
sults.
The obtained results of radiological assays
were compared to reference test findings. Results
were arranged in the table, including TP, TN, FP,
and FN results. Then, in order to evaluate the dia-
gnostic accuracy of the method, the following pa-
rameters were calculated: sensitivity (Se), specifi-
city (Sp), accuracy (Acc), level of reliability of po-
sitive result (LR+), level of reliability of negative
result (LR–), and diagnostic odds ratio (DOR), all
expressed with 95% confidence intervals (CI). The
sign test was applied for comparing the diagnostic
accuracy of respective tests. This test concerns re-
lated variables when the results of both CT and
PET-CT in a given patient are similar. Statistical
analysis was performed using the Statistica for
Windows 6.5 software.
Results
The mean age in the studied group of 99 pa-
tients with primary lung carncer was 64.2 years
(41–88 years). Men comprised 70.7% of the patients
in this group.
The location of the lesion was precisely descri-
bed in each patient. The tumour was located in the
right upper lobe in 37/99 patients (37.3%), in the
right lower or median lobe in 22/99 persons
(22.2%), in the upper left lobe in 25/99 cases
(25.2%), and in the left lower lobe in 15/99 sub-
jects (15.1%).
The main tumour dimension was measured for
all 99 patients. Mean tumour size was 41.7 mm.
Tumours were then divided in two groups — ha-
ving between 10 mm and 30 mm in diameter, and
of more than 30 mm in size.
Lymph node dimensions were measured along
their short axis. During FDG PET-CT scan, the SUV
value for each tumour was assessed. Sixty out of
99 studied patients were operated on, with resec-
tion of all lymph node groups accessible during the
procedure. In two patients, surgical procedure fol-
lowed chemotherapy. Histopathological analysis of
all 99 tumours revealed 27 cases of adenocarcino-
ma (27.3%) and 30 cases of squamous cell carci-
noma (30.3%), whereas in 42 patients (42.3%) the
diagnosis of “non-small cell cancer not otherwise
specified” was made.
Computed tomography scanning was perfor-
med in 99 patients, of which 59 persons were al-
ready diagnosed with lung cancer during previo-
us investigation, and a further 40 persons were re-
ferred for diagnostics of focal lung lesions but had
no diagnosis as yet. Analysis of SUVmax values
was performed separately in centres A and B. The
obtained mean SUVmax values in the respective
centres after the first phase investigations were 7.5
(A) and 7.6 (B) for adenocarcinoma, 11.7 (A) and
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17.3 (B) for squamous cell carcinoma, and 8.6 (A)
and 13.9 (B) for non-small cell cancer NOS. In
the delayed phase test, the mean value of SUVmax
measured in centre B was 14.9 for adenocarcino-
ma, 17.9 for squamous cell carcinoma, and 18.8
for non-small cell cancer NOS. All tumour types
demonstrated increased FDG uptake during the
second phase evaluation. No increase in FDG
uptake within the lesion (FN) was observed in 3
patients (3.0%)
The following surgical procedures were per-
formed: lobectomy — 47/60 patients (78.3%), bi-
lobectomy in 3/60 patients (5.0%), and pneumo-
nectomy in 10/60 subjects (16.6%).
Adenocarcinoma was the most common type
of tumour in the operated patients, concerning
92.6% of subjects (25/27).
In 39 patients (39.3%) no surgical resection
was performed due to the presence of distant me-
tastases, poor general condition, or lack of patient
consent for surgery. Staging was assigned accor-
ding to the sixth edition of the TNM classifica-
tion presented by Union for International Cancer
Control (UICC) in December 2006, and by AJCC
in June 2007.
T descriptor
Tumour size was assigned using the greatest
identified dimension of the lesion. According to the
intraoperative assessment, T1 stage was assigned
in 28 patients (28.2%), T2 in 51 persons (51.5%),
T3 in 11 cases (11.1%), and T4 in one subject (1.0%).
The T descriptor was assigned correctly by CT in
94 patients (94.9%), and by PET-CT in 96 subjects
(96.9%). Incorrect T-stage assignment by CT occur-
red in 5 persons (5.0%), including one T1 patient
(3.6%), three T2 subjects (5.9%), and one T4 patient
(11.1%). Incorrect T-staging by PET-CT was noted
in three persons, including two T2 patients (3.9%)
and one person with a T4 tumour (9.1%).
Overall analysis revealed that four CT and
three PET-CT investigations showed a smaller tu-
mour size as compared to pathological staging
(pTNM). Underestimation of the tumour size was
due to intraoperatively detected infiltration of ne-
arby structures, including main vessels, which had
not previously been identified by imaging techni-
ques. One CT investigation suggested a bigger tu-
mour size as compared to intraoperative data. Ove-
restimation of the tumour size was due to infiltra-
tion of the nearby structures, previously described
in CT but not confirmed by the surgeon. Tumour
size was underestimated by CT assessment in 4.0%
of cases in the entire group, and by PET-CT in 3.0%
of cases. Overestimated values were found in 1.0%
of cases, as assessed by CT (Tab. 1).
N-descriptor
Regional lymph node involvement was ultima-
tely described as N0 in 51 patients (51.5%), N1 in
23 cases (23.2%), N2 in 18 cases (18. 2%), and N3
in 7 cases (7.1%). Correct N-staging was provided
by CT scanning in 83 patients (83.8%) and by PET-
CT in 94 patients (94.9%). Incorrect staging of this
parameter was observed in 16 patients (16.2%)
after CT investigation and in five persons (5.1%)
after PET-CT scanning. Underestimation of nodal
involvement by CT was observed in 11 patients
(FN), and overestimation in five patients (FP). Fol-
lowing PET-CT scanning, the N-descriptor was
underestimated in three patients (FN), and overe-
stimated in two patients (FP).
Sensitivity of the PET-CT test was 0.94, and
that of CT was 0.76. This means that the probabi-
lity of positive PET-CT result in patients having
regional nodal metastases is 94% (95% confiden-
ce interval [CI]: 83–98), and the respective value
for CT testing is 76% (95% CI: 61–86). Specificity
of PET-CT investigation was 0.96, which means
that the probability of a negative imaging result in
a patient having no nodal metastases is 96% (95%
CI: 87–99). Specificity of computed tomography
testing was 0.90. Thus, the probability of a negati-
ve CT result in a patient in whom reference test
shows no presence of mediastinal lymph node
metastases is 90% (95% CI: 80–96).
Table 1. Details of accuracy of tumor (T) status: CT compared with integrated PET-CT and pathological staging (pT), no sta-
tistically significant difference between CT and PET-CT
Correctly staged CT/CT PET-CT pT
T1 28 28 28
T2 49 50 51
T3 10 10 11
T4 7 8 9
Total (99) 94/99 (95%) 96/99 (97%) 99 (100%)
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The calculated value of the reliability index
of a positive result by PET-CT scanning was 24.8.
Therefore, the probability of obtaining a positive
CT finding in a patient having nodal metastases is
24.8 times higher than the respective probability
in a subject with no lymph node engagement. Re-
spective index calculated for CT diagnostics was
8.2, which means that the probability of a positive
CT finding is 8.2 times higher in a patient having
metastases to lymph nodes than it is in a person in
whom histopathological analysis disclosed no pre-
sence of tumour cells in lymph nodes.
Accuracy of CT imaging in lymph node eva-
luation was 84% (95% CI: 75–90), whereas the
respective value for FDG PET-CT was 95% (95%
CI: 89–99). Reliability index of a negative PET-
CT result was 0.1, which means that the proba-
bility of obtaining a negative radiology result in
a patient who does have nodal metastases is only
0.1 of the probability of that of a patient having
metastases. The reliability index of a negative CT
result was 0.3, which means that the probability
of obtaining a negative radiology result in a pa-
tient who does have nodal metastases is only 0.3
of the probability of that of a patient having me-
tastases. The calculated diagnostic accuracy for
PET-CT was 95% (95% CI: 89–99), and the respec-
tive index for CT was 84% (95% CI: 75–90). The
difference between those two values was statisti-
cally significant (p = 0.0055).
Diagnostic odds ratio for PET-CT was 248,
and for CT was 27.3; therefore, the probability
of correct staging for the N-descriptor is nine ti-
mes higher when using PET-CT than it is for CT
alone. In order to correctly N-stage one more
patient having lung cancer, PET-CT scanning
must be performed instead of CT in nine persons.
Positive predictive value (PPV) was 87.2% for
CT; therefore, the probability of true nodal en-
gagement in a patient having enlarged mediasti-
nal lymph nodes is 87.2% (95% CI: 72–94). Ne-
gative predictive value (NPV) for CT was 81.7%,
which means that the probability of not having
nodal metastases for a person with no nodal en-
largement visualised by CT is 81.7% (95% CI: 70–
89). The positive predictive value for PET-CT
was 95.5%. Therefore, the probability that a pa-
tient with increased mediastinal lymph node
uptake has metastases in this region is 95.5 (95%
CI: 85–99).
The negative predictive value for the same
diagnostic modality was 94.4%, which is also the
probability rate of absence of metastases in a pa-
tient in whom no increase in FDG uptake was ob-
served in mediastinum (95% CI 85; 98) (Tab. 2).
Table 2. Sensitivities, specificities, positive likelihood ratio
(LR+), negative likelihood ratio (LR–), accuracy,
diagnostic odds ratio (DOR), positive predictive
values (PPV), negative predictive values (NPV) for
the detection of malignant lymph nodes (N) of CT
and integrated PET-CT, statistically significant dif-
ference between CT and PET-CT (p = 0.0055)
CT/CT PET-CT
Se (95% CI) 76% (61; 86) 94% (83; 98)
Sp (95% CI) 90% (80; 96) 96% (87; 99)
Lr+ 8,2 24,8
Lr– 0,3 0,1
Acc (95% CI) 84% (75; 90) 95% (89; 99)
DOR 27,3 248
PPV 87% (72; 94) 96% (85; 99)
NPV 82% (70; 89) 94% (85; 98)
M-descriptor
Distant metastases were detected in 18 pa-
tients (18.2%). Computed tomography scanning
results suggested the presence of metastases out-
side the mediastinum (M1) in seven subjects. Of
those, three had false positive results (metasta-
ses to contralateral lung, to adrenal glands or
bone), and in four cases the results were truly
positive, with brain, contralateral lung, adrenal
gland, or bone metastases present. The sugge-
stion of M1 stage was made by PET-CT in 19 ca-
ses. A false positive result was identified in one
person, with suspected contralateral lung meta-
stasis. True positive results were found in 18
patients, including bone metastases in 7 persons,
contralateral lung engagement in 4 persons, ad-
renal gland metastases in 3 persons, supraclavi-
cular lymph node metastases in 2 persons, and
axillary lymph node engagement and brain me-
tastases in one person each. Computed tomogra-
phy scanning underestimated the M-stage in 13
patients (13.1%) and overestimated it in three
subjects (3.0%).
There were no cases of M-stage underestima-
tion by PET-CT, but in one patient M-staging was
overestimated (1.0%). Based on these data, the cor-
rect M-staging was more common when using PET-
CT (98 patients) as compared to CT alone (83 pa-
tients). Correct M-staging by CT was obtained in
83 subjects, which yielded an accuracy of 83.8%
(95% CI: 75–90). When using PET-CT, correct M-
staging was achieved in 98 patients, with an accu-
racy of 98.9% (95% CI: 95–100). The difference
between these values was statistically significant
(p = 0.0012) (Tab. 3).
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Total TNM stage
Most patients in the studied group were assi-
gned to TNM stage I, following assessment by CT,
PET-CT, and pTNM. Computed tomography alone
provided correct staging in 67/99 patients (67.7%),
and PET-CT in 88/99 subjects (88.9%). The calcu-
lated diagnostic accuracy was 68% for CT (95% CI:
58–76) and 89% for PET-CT (95% CI: 81–94). The
difference was statistically significant.
Computed tomography alone was most accu-
rate for TNM staging in patients assigned to stage
IA or IB, and the least accurate for stage IV patients.
As for PET-CT, the greatest accuracy was noted for
stages IA, IIIA, and IV (Tab. 4).
Discussion
Surgery remains the main radical treatment
option in non-small cell lung cancer. Radiological
assessment, tumour biopsy, and staging according
to TNM classification should be performed prior
to the planned operative intervention. Correct sta-
ging is a prerequisite for optimal and successful
treatment [14].
Surgical intervention is aimed at radical resec-
tion, and lobectomy remains a standard in non-
small cell cancer. Segmentectomy may be perfor-
med in peripheral lesions of low stage but only if
the patient has contraindications for radical sur-
gery.
A tumour is considered resectable if it can be
separated from the surrounding structures. The
estimated sensitivity and specificity of computed
tomography in the assessment of thoracic wall in-
filtration is 38–87% and 40–90%, respectively [15].
Imaging by PET-CT often permits differentiation
between neoplastic infiltration and uninvolved
surrounding structures. In the presented study,
correct T-staging was more often achieved by PET-
CT (96/99 patients) than by CT alone (94/99 pa-
tients). Accuracy of PET-CT staging was 96.9% and
that of CT was 94.9%, with no statistically signifi-
cant difference.
Computed tomography is not sufficiently spe-
cific in the assessment of involved mediastinal
lymph nodes. This diagnostic modality enables
good visualisation of lymph node location, shape,
and dimensions, and can be used for identification
of appropriate lymph nodes for biopsy [16, 17].
Most authors consider 10 mm as the threshold va-
lue of the lymph node size, along its shortest axis
[18, 19]. More precise assessment can be perfor-
med when using different thresholds for respecti-
ve lymph node groups, as delineated by the Ameri-
can Thoracic Society [20]. For example, 13 mm
along the shorter axis is an upper limit for lymph
nodes situated below the tracheal bifurcation and
for pretracheal ones. With this threshold respected,
the number of false positive results is decreased.
Not only the size but also the location of in-
volved lymph nodes is of prognostic significance
[21]. Stage N1 lymph nodes can most often be re-
moved during the operation, but this can be tech-
nically difficult if they adhere to the pulmonary
artery; pneumonectomy is the best option in such
cases.
Table 4. Overall staging at CT and integrated PET/CT in patients with lung cancer: correctly staged (1), overstaged (2), un-
derstaged (3),statistically significant difference between CT and PET-CT (p = 0.0002)
CT/CT CT/CT CT/CT PET-CT PET-CT PET-CT
1 2 3 1 2 3
Histological type
Adenocarcinoma 21 4 2 22 4 1
Squamous 20 3 7 27 0 3
Subtype not defined 26 2 14 39 3 0
Total 67 (68%) 9 23 88 (89%) 7 4
Table 3. Details of accuracy of metastatic (M) status: CT compared with integrated PET-CT and pathological staging (pM),
statistically significant difference between CT and PET-CT (p = 0.0012)
CT/CT PET-CT pM CT/CT PET-CT pM
M status M0 M0 M0 M1 M1 M1
Total 92 80 81 7 19 18
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An important aspect in N-staging accuracy is
the histological type of the tumour. Mori et al. fo-
und that lymph nodes containing metastases of
lung adenocarcinoma are often normal in size in
CT pictures [22]. A higher CT sensitivity for N-sta-
ging was observed for squamous cell carcinoma.
To sum up, the applicability of CT and PET-
CT in the assessment of mediastinal lymph nodes
depends on the lymph node dimensions, location,
and type of tumour. A report from the Institute for
Clinical Evaluative Sciences (ICES) points out the
importance of PET-CT in nodal staging in patients
with lung cancer, which is superior to that of CT.
The combined modality is useful for assessment
of lymph node metastases, irrespective of their size
[23, 24]. However, many authors reported a high
number of false positive results of nodal staging
by PET-CT [25]. Fewer false positive results were
observed for lymph nodes in upper mediastinum.
It should be remembered that inflammatory chan-
ges in lymph nodes can give false positive results
in PET-CT scans, which can potentially disquali-
fy patients eligible for surgery.
In the presented study, the calculated diagno-
stic accuracy of PET-CT for N-staging was 95%
(95% CI: 89–99), and the respective value for CT
was 84% (95% CI: 75–90), with a statistically si-
gnificant difference (p = 0.0055).
Metastases from lung cancer pose a serious
diagnostic dilemma and may be found in various
organs. Thus, whole body PET-CT scanning faci-
litates correct M-staging.
Focal lesions are often detected in ipsi- or
contralateral lung in patients having lung cancer.
Adequate assessment of additional focal lung le-
sions in patients with non-small cell lung cancer
is of utmost importance in therapeutic strategy
planning.
Those additional lesions can be of benign
(non-neoplastic) character and may represent ano-
ther primary lung cancer or metastases from lung
cancer or from the malignancy localised in ano-
ther organ. Caretta et al. performed a histopatho-
logical analysis of additional focal lung lesions as-
sociated with lung cancer [26]. One of the more
intriguing findings was the presence of intrapul-
monary lymph nodes, identified histopathologi-
cally. Many other lesions turned out to be of post-
inflammatory character, radiologically imitating
cancer metastases.
These authors suggest that scrupulous inve-
stigation of accessory lung lesions is indicated in
all patients considered for surgery.
In the presented study, only four patients (4/
99) had contralateral lung metastases. Computed
tomography correctly identified one of them, whe-
reas PET-CT detected all the lesions.
Horejs reported that in 25% of patients with
low stage lung cancer (no regional lymph node
metastases) distant metastases could be found by
CT [27, 28].
Metastases to adrenal glands, liver, brain, bo-
nes, or lymph nodes are a common finding in pa-
tients with lung cancer. Numerous reports from
literature suggest that even patients with no clini-
cal signs or symptoms should be investigated for
potential metastases from lung cancer. Adenocar-
cinoma gives distant metastases more frequently
than other histological types of NSCLC [29, 30].
Squamous cell carcinoma, however, often gives
distant metastases at a later timepoint [31]. Any
clinical information can be of great help for radio-
logists for interpretation of the obtained pictures.
In the presented study, adrenal gland metasta-
ses from primary lung cancer were identified in 3/
99 patients (3%). Computed tomography yielded
two true positive, and PET-CT three true positive
results.
Adrenal glands are organs of particular impor-
tance as they can harbour many benign lesions
(adenomas, hyperplastic changes) that imitate can-
cer metastases [32].
Metastases in adrenal glands can most often
be detected in thorax CT, if only the organs are
within the analysis gate. The presence of adrenal
metastases can be detected by CT in 5–10% of pa-
tients [33, 34]. The lesions are mostly unilateral,
with bilateral metastases detected in not more than
3% patients. Adrenal gland adenomas are common
findings and can be identified in 2–10% of subjects
in the general population [35]. These can be erro-
neously interpreted as cancer metastases. An ad-
renal focal lesion of density less than 10 HU befo-
re contrast medium administration, with more than
50% contrast elimination after 10 minutes, as com-
pared to elimination after 1 min, is believed to be
of benign character [36, 37]. Magnetic resonance
imaging (MRI) is another diagnostic modality that
can be used for the investigation of adrenal glands.
Similarly to CT, MRI pictures of adrenal glands
visualise fatty tissue contained in the organ, with
potential focal lesions. In cases of equivocal CT and
MRI findings, PET-CT scanning can be of value,
as it determines the metabolic activity of any iden-
tified lesion. If PET-CT scans yield unclear pictu-
res, biopsy of the adrenal gland is the only availa-
ble investigation left for verification of the lesion
character. Removal of the metastatically affected
adrenal gland can prolong the patient’s life or even
be curative [38].
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In the presented study, brain metastases were
identified by CT and MRI in a single patient out of
all 99 subjects (1%). The diagnosis was made be-
fore PET-CT scan.
Brain metastases from lung cancer may be pre-
sent in as many as 18% of patients [39, 40], with
most of them presenting neurological symptoms.
Kormas et al. found that 6% of patients with non-
small cell lung cancer, with no neurological symp-
toms, had brain metastases. These were identified
at the beginning of diagnostic procedures in 3% of
patients, and in a further 3% of subjects brain
metastases were found a year later, during follow-
up [41]. Ferrigno and Buccheri reported the pre-
sence of brain metastases in as many as 15% of
patients with low stage lung cancer [42]. Brain
metastases can be invisible in CT pictures [43, 44],
and MRI is perceived as a more accurate and sen-
sitive diagnostic modality.
Similarly to adrenal gland metastases, surgi-
cal removal of an isolated brain metastatic focus
can prolong life or be curative in patients with re-
sectable lung cancer [45, 46].
In the current study, bone metastases were
found in 7/99 patients (7%). Computed tomogra-
phy yielded one true positive result; bone structu-
res harbouring metastatic lesions were not investi-
gated radiologically in the remaining six patients.
Combined PET-CT scan returned seven true posi-
tive results.
Most patients with bone metastases complain
of pain, which suggests tumour spread. However,
bone metastases may remain asymptomatic in 40%
of patients [47, 48]. In any patient with pain symp-
tomatology, scintigraphy and MRI should be con-
sidered, along with measurement of alkaline pho-
sphatase activity [49–51]. Scintigraphy has a high
sensitivity in this setting (90%) but with lower
specificity (61%) [52, 53]. False positive results of
scintigraphy or PET-CT scans can be due to local
tissue degeneration as well as the presence of in-
flammatory or posttraumatic lesions. False positi-
ve PET-CT findings can be found even in some
patients with osteolytic lesions [54]. Nevertheless,
FDG PET-CT is believed to be the optimal diagno-
stic modality for detection of bony metastases un-
detected by other methods, and is superior to CT
and scintigraphy in skeletal system investigation
[55]. It is commonly suggested that FDG PET-CT
scanning should be performed routinely as part of
non-small cell lung cancer staging [56].
Positron emission tomography combined with
computed tomography is of great value in the de-
tection of metastatic lesions, particularly in adre-
nal glands and the skeletal system. Verhagen et al.
[57] reported the presence of metastases detected
by PET-CT in 15% of paients, where other diagno-
stic modalities showed no abnormalities.
In the presented study, extrapulmonary lymph
node metastases were also found, including lesions
in supraclavicular lymph nodes in two persons,
and in the axillary lymph node in another patient.
Those lymph nodes were described as normal
(not enlarged) in CT scans but identified as meta-
static foci in PET-CT due to increased FDG uptake.
High accuracy of PET-CT in M-staging was
observed in the presented study (98.9%) as com-
pared to CT alone (83.8%).
Cerfolio et al. investigated the accuracy of
PET-CT in staging in non-small cell cancer in 129
subjects [58]. The accuracy of positron emission
tomography combined with computed tomography
was superior to that of CT alone in the assessment
of both T and N-descriptors as well as in overall TNM
staging, with statistically significant differences.
Lardinois et al. also compared PET-CT with
CT, and found the former modality to be more ac-
curate in staging for T, N, and M descriptors [59].
Shim et al. demonstrated that PET-CT is signi-
ficantly more accurate in N-staging and overall
TNM staging but not superior to CT in the asses-
sment of tumour size (T-descriptor) [60]. Similar
results were found in the presented study.
Many authors consider PET-CT and CT to have
similar accuracy in TNM staging but point to su-
perior PET-CT results in the assessment of media-
stinal lymph nodes (N-stage).
Van Tinteren et al. included PET-CT into ro-
utine diagnostics, and observed a reduction in
the number of unnecessary procedures from 41%
to 21%. According to Viney et al., PET-CT scan-
ning results affect the choice of therapeutic pro-
cedures in 20% of stage I or II patients but do
not reduce the number of thoracotomies perfor-
med, since results of PET-CT scanning are not
sufficient for disqualification from surgery. Au-
stralian researchers reclassified 14% of patients
following PET-CT scanning [61]. In the presen-
ted study, PET-CT investigations were conclusi-
ve for nonresectability of the lesion in 22/99 pa-
tients (22%).
Similarly to the previously mentioned reports,
the authors of the presented study noted a signifi-
cant reduction in unnecessary thoracotomy proce-
dures following investigation by PET-CT.
In the presented study, PET-CT scanning de-
monstrated nonresectability of the lesion in 22/99
patients (22%).
Herder et al. did not observe statistically si-
gnificant differences in TNM stage between pa-
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tients who underwent PET-CT scanning and tho-
se who did not [62].
However, differences were observed between
the duration and cost of diagnostic procedures.
Average duration of diagnostic sequence decreased
from 23 to 14 days, and the number of patients
requiring more than one investigation for lymph
node assessment was aslo significantly lower.
False positive results of PET-CT scanning can
be obtained in cases of infections or inflammatory
lesions.
Therefore, all positive PET-CT scan results
should be, if possible, verified histopathological-
ly. Potential candidates for surgery, with positive
PET-CT lymph node scans should be biopsied thro-
ugh mediastinoscopy for definitive confirmation of
metastatic lymph node involvement. Verification
should also be performed in cases of any suspec-
ted extrathoracic lesions found by CT, MRI, or scin-
tigraphy. False negative results are observed ma-
inly if nodal, pulmonary, or other metastatic le-
sions are of small size.
In the presented study, increased FDG uptake
was not found in malignant tumours in PET-CT
scans in three patients (3%) (FN). In two of those,
the tumour was histologically of adenocarcinoma
type, and in the remaining patient the lesion was
11 mm in diameter.
According to Nomori et al., PET-CT cannot
detect metastatic lesions smaller than 4 mm [63].
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